drugset / Trial / NCT04857827

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

NCT04857827

Phase 2 Completed 30 enrolled Qlaris Bio, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma

Timeline

Start
2021-09-15
Primary completion
2022-08-26
Completion
2022-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS-101 Unknown 1 % Other
Subject QLS-101 Unknown 2 % Other
Comparator Timolol Other / unclassified 0.5 % Other

Indications